2014-04-15 16:07:07 UTC

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for HCV with Cirrhosis

April 17, 2014

Fred Poordad and colleagues report in New England Journal of Medicine that multitargeted therapy with the use of three new interferon-free, antiviral agents and ribavirin resulted in high rates of sustained virologic response.

Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. Fred Poordad and colleagues evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis. They report in New England Journal of Medicine that multitargeted therapy with the use of three new interferon-free, antiviral agents and ribavirin resulted in high rates of sustained virologic response. Drug discontinuations due to adverse events were infrequent. 

New England Journal of Medicine 2014: DOI: 10.1056/NEJMoa1402869

More on Cirrhosis

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Blog: Diagnosis, Pathogenesis and Treatment of Hepatorenal Syndrome in Patients With Cirrhosis

Jan. 30, 2018

New concepts and developments for diagnosis and assessment of renal function in patients with cirrhosis. Read more on the AGA Journals Blog.

Image Challenge: Cullen's Sign

Jan. 22, 2018

What caused a 56-year-old man with a previous history of cirrhosis to present with a large volume of ascites and periumbilical ecchymosis?